PT1191025E - Cristais de lansoprazol - Google Patents

Cristais de lansoprazol

Info

Publication number
PT1191025E
PT1191025E PT00942388T PT00942388T PT1191025E PT 1191025 E PT1191025 E PT 1191025E PT 00942388 T PT00942388 T PT 00942388T PT 00942388 T PT00942388 T PT 00942388T PT 1191025 E PT1191025 E PT 1191025E
Authority
PT
Portugal
Prior art keywords
crystals
lansoprazol
pyridinylümethylüsulfinyl
2äää3
trifluoroethoxy
Prior art date
Application number
PT00942388T
Other languages
English (en)
Inventor
Akira Fujishima
Aoki Isao
Kamiyama Keiji
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PT1191025E publication Critical patent/PT1191025E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dental Preparations (AREA)
PT00942388T 1999-06-30 2000-06-29 Cristais de lansoprazol PT1191025E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP18640399 1999-06-30

Publications (1)

Publication Number Publication Date
PT1191025E true PT1191025E (pt) 2005-09-30

Family

ID=16187808

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00942388T PT1191025E (pt) 1999-06-30 2000-06-29 Cristais de lansoprazol

Country Status (9)

Country Link
US (4) US6608092B1 (pt)
EP (1) EP1191025B1 (pt)
AT (1) ATE298334T1 (pt)
AU (1) AU5705700A (pt)
CA (1) CA2375091A1 (pt)
DE (1) DE60020967T2 (pt)
ES (1) ES2240113T3 (pt)
PT (1) PT1191025E (pt)
WO (1) WO2001002389A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20040224989A1 (en) * 1999-01-29 2004-11-11 Barberich Timothy J. S-lansoprazole compositions and methods
TWI275587B (en) * 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
PT1191025E (pt) * 1999-06-30 2005-09-30 Takeda Pharmaceutical Cristais de lansoprazol
CA2386277A1 (en) * 1999-10-01 2001-04-12 Natco Pharma Limited An improved pharmaceutical composition and a process for its preparation
AU2001252595A1 (en) 2000-04-28 2001-11-12 Takeda Chemical Industries Ltd. Process for producing optically active sulfoxide derivative
ES2511774T3 (es) 2000-05-15 2014-10-23 Takeda Pharmaceutical Company Limited Formas cristalinas de (R)-lansoprazol
WO2002012225A1 (fr) * 2000-08-04 2002-02-14 Takeda Chemical Industries, Ltd. Sels de composé à base de benzimidazole et leurs applications
DK1337525T3 (da) * 2000-12-01 2011-09-19 Takeda Pharmaceutical Fremgangsmåde til krystallisering af (R)- eller (S)-lansoprazol
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US6897208B2 (en) 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
US20040010151A1 (en) * 2002-03-27 2004-01-15 Nina Finkelstein Lansoprazole polymorphs and processes for preparation thereof
EP1552833B1 (en) * 2002-10-16 2016-12-28 Takeda Pharmaceutical Company Limited Process for producing an amorphous optically active isomer of lansoprazole
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
AU2004257864A1 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2531564C (en) * 2003-07-18 2016-01-19 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
CA2554271A1 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
JP2007532677A (ja) * 2004-04-16 2007-11-15 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤、および運動促進薬の組み合わせ
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
WO2010056059A2 (en) * 2008-11-14 2010-05-20 Hanmi Pharm. Co., Ltd. Novel crystalline dexlansoprazole and pharmaceutical composition comprising same
CN104997739A (zh) * 2015-08-31 2015-10-28 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化系统疾病的药物兰索拉唑组合物冻干粉针剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DK171989B1 (da) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) 1994-11-28 1995-01-11 Astra Ab Resolution
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
AU744260B2 (en) 1998-01-23 2002-02-21 Sphelar Power Corporation Solar battery module for optical electrolysis device and optical electrolysis device
EP1056457A4 (en) * 1998-01-30 2006-10-25 Sepracor Inc S-LANSOPRAZOLE COMPOSITIONS AND METHODS OF USE
WO1999056698A2 (en) 1998-05-06 1999-11-11 Københavns Universitet Treatment of celiac disease
TWI275587B (en) * 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
PT1191025E (pt) * 1999-06-30 2005-09-30 Takeda Pharmaceutical Cristais de lansoprazol

Also Published As

Publication number Publication date
DE60020967T2 (de) 2006-05-04
US20040082791A1 (en) 2004-04-29
US7189744B2 (en) 2007-03-13
EP1191025A4 (en) 2003-07-09
ES2240113T3 (es) 2005-10-16
EP1191025A1 (en) 2002-03-27
US20070155796A1 (en) 2007-07-05
CA2375091A1 (en) 2001-01-11
AU5705700A (en) 2001-01-22
DE60020967D1 (de) 2005-07-28
EP1191025B1 (en) 2005-06-22
ATE298334T1 (de) 2005-07-15
US6608092B1 (en) 2003-08-19
WO2001002389A1 (fr) 2001-01-11
US6903122B2 (en) 2005-06-07
US20050171162A1 (en) 2005-08-04

Similar Documents

Publication Publication Date Title
PT1191025E (pt) Cristais de lansoprazol
NO20016087D0 (no) Benzimidazolforbindelsekrystall
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
ID26043A (id) Turunan-turunan 1,3,5-triazina tertrisubstitusi untuk pengobatan infeksi-infeksi hiv
FI903331A0 (fi) Substituerade kinazolinoner, vilka aer anvaendbara som angiotensin-ii-antagonister.
ATE342263T1 (de) Salze von benzimidazol-derivaten und deren verwendung
PE14199A1 (es) Agonistas de 5-ht1f
DK1200418T3 (da) Nematodicide trifluorbutener
DK0976722T3 (da) Benzamidin-derivater
DZ3001A1 (fr) Sel de potassium d'oméprazole-(S).
DK506587D0 (da) Imidderivater
DK0810220T3 (da) Arylacrylamidderivater som 5-HT1-agonister eller -antagonister
BR0209901A (pt) Processos para a sìntese de derivados de 2,3-dihidro-1,4-dioxino-[2,3-f] quinolina
ATE250021T1 (de) Hydroxycyclopentanone
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
DE69936052D1 (de) N1 modifizierte glycopeptide
ID25478A (id) Agonis 5-ht1f
BR9902096A (pt) Pitazóis.
DK1085019T3 (da) Omoprazolsyntese
BR0211620A (pt) Imidazopiridinas substituìdas por alquila para o tratamento de distúrbios gastrointestinais
ATE242227T1 (de) Tetrahydrofuranderivate
ITMI992457A0 (it) Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidrois ochinolin-3-carbossiammide
TH69761B (th) ผลึกสารประกอบเบนซิมิแดซอล
PT1140932E (pt) Derivados de 1,8-benzonaftiridina
CY1110529T1 (el) Παρασκευη ν-υποκατεστημενων 2,7-διαλκυλο-4-υδροξυ-5-αμινο-8-αρυλοοκτανοϋλαμιδιων